The summer of 2020 has been a busy one for US biopharmaceutical company initial public offerings, but after 14 in June and 12 in July there were just six in August – although that’s still the third most active month for IPOs by drug developers. The first IPO of September was a small one by PainReform in Herzliya, Israel, which grossed just $20m.
However, three special purpose acquisition companies (SPACs) also went public during the first few days of this month. The largest SPAC offering was launched on 1 September by CM Life...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?